Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Valiant Laboratories
Small Cap•77 Employees•IPO 2023
Current Price
₹55.79
3.31 (6.31%)Updated
Today's Range
₹53.01
₹56.98
₹55.79
52 Week Range
52W Low₹49.51
52W High₹124.40
₹55.79
Downside12.68%
Upside122.98%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹321.37 Cr
Market Cap
Total market value of companyP/E Ratio
2524.21
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
1.42
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹-0.05
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
-0.95%
ROCE
Return on Capital Employed. >15% is goodNet Margin
0.08%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
148.00%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
457.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.52
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹50.08
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
74.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Promoter confidence remains high with 74.9% consistent shareholding.
- •Robust quarterly sales growth of 148% to 46.8 Cr.
Weaknesses
5 points- •Exceptionally high P/E ratio of 3357.61 suggests significant overvaluation.
- •Negative ROE (-1.43%) and ROCE (-0.95%) indicate inefficient capital utilization.
Opportunities
5 points- •Capitalize on inherent growth drivers within the expanding Pharmaceuticals sector.
- •Substantial room for market share capture as a small industry player.
Threats
4 points- •Intense competition from larger, established pharmaceutical players with greater resources.
- •Highly regulated Pharmaceuticals industry poses ongoing risks from policy changes.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹65.45 | +₹9.66 | +17.31% |
| R3 | ₹61.48 | +₹5.69 | +10.20% |
| R2 | ₹59.23 | +₹3.44 | +6.17% |
| R1 | ₹57.51 | +₹1.72 | +3.08% |
| PIVOT | ₹55.26 | -0.53 | -0.95% |
| CURRENT | ₹55.79 | - | - |
| S1 | ₹45.60 | -₹10.19 | -18.26% |
| S2 | ₹49.57 | -₹6.22 | -11.15% |
| S3 | ₹51.29 | -₹4.50 | -8.07% |
| S4 | ₹53.54 | -₹2.25 | -4.03% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+9.5% vs avg
0.66L
(04 Mar 2026)Delivery %-15.8% vs avg
56.5%
(04 Mar 2026)Avg Volume (20D)20-day average
0.60L
(04 Feb - 04 Mar)Avg Delivery %Trend ↓
72.3%
(04 Feb - 04 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Medico Remedies Ltd
65.80 %
Highest Dividend Yield
Sun Pharmaceutical Industries Ltd
0.91 %
Peer Comparison
| Company Name |
|---|
 Albert David Ltd |
 |
 Bafna Pharmaceuticals Ltd |
 Haleos Labs Limited |
 Lyka Labs Ltd |
 Medicamen Biotech Ltd |
 Medico Remedies Ltd |
 Nectar Lifescience Ltd |
 SMS Lifesciences India Ltd |
 Sun Pharmaceutical Industries Ltd |
 Zim Laboratories Ltd |
About
Valiant Laboratories Ltd
Valiant Laboratories Limited is an active pharmaceutical ingredient (API) and bulk drug manufacturing company with a global reach, headquartered in Mumbai, India. Their primary focus is on the production and distribution of paracetamol, a widely used analgesic and antipyretic drug. They manufacture paracetamol to meet the standards of various pharmacopoeias, including those of India, Britain, Europe, and the United States, ensuring compliance with diverse regulatory requirements across different markets.
The company's paracetamol production caters to a broad range of therapeutic applications. It is used to treat a variety of conditions including headaches, muscle aches, arthritis, backaches, toothaches, cold symptoms, and fever. This broad applicability contributes to a large potential market for their product.
Beyond paracetamol, Valiant Laboratories also offers a portfolio of specialty chemicals, though the specifics of these offerings are not detailed in the provided information. This diversification suggests a commitment to offering a wider range of products and services within the chemical and pharmaceutical industries.
Established in 1980 as Bharat Chemicals, the company rebranded as Valiant Laboratories Limited in August 2021. This rebranding may reflect a strategic shift in focus or an effort to enhance brand image and market positioning. Currently, Valiant Laboratories Limited operates as a subsidiary of Dhanvallabh Ventures LLP, indicating a larger corporate structure and potential access to greater resources and support.
In summary, Valiant Laboratories Limited is a well-established pharmaceutical company specializing in the manufacture and distribution of high-quality paracetamol and other specialty chemicals, supplying to a global market and meeting the stringent standards of multiple international pharmacopoeias. Their long history and recent rebranding demonstrate a commitment to sustained growth and innovation within the pharmaceutical industry.
COMPANY FACTS - VALIANTLAB
Registered Address
104, 1st Floor, Udyog Kshetra, Above Krishna Motors, Near D-mart, Mulund Goregaon Link Road, Mulund (West)
Mumbai
MAHARASHTRA
IN
Tel: 912249712001
Website:https://valiantlabs.in/
Investor Relations:https://valiantlabs.in/investors/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 77
IPO Date: 06/10/2023
MANAGEMENT - VALIANTLAB
Mr. Paresh Shah
Chief Financial Officer, Executive Director
Ms. Prajakta Patil
Compliance Officer, Company Secretary
Shri. Santosh Vora
Managing Director, Executive Director
Ms. Archana Koli
Purchase Manager
Mr. Chandrakant Mandhare
Head - Accounts and Finance
Ms. Kiran Mudaliar
Assistant Manager - Accounts
Mr. Bhanudas Patil
Quality Control Manager
Mr. Nilesh Patil
Head - Research and Development
Mr. Bhupendra Raul
Quality Assurance Manager
Mr. Jyotibhushan Singh
Head - Unit
Mr. Sandeep Gupta
Non-Executive Director
Mr. Shantilal Vora
Non-Executive Director
Investor Questions Answered
Valiant Laboratories Ltd (VALIANTLAB) Stock FAQs
Get answers to the most common questions about Valiant Laboratories Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Valiant Laboratories Ltd (VALIANTLAB) is ₹55.79. Today, the stock has gained by ₹3.31 (6.31%), trading in a range of ₹53.01 to ₹56.98. The stock opened at ₹53.01 with a trading volume of 11,805 shares.
Valiant Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹321.37 crores, P/E ratio of 2524.21, ROE of 0.00%, and ROCE of -0.95%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Valiant Laboratories Ltd (VALIANTLAB) is ₹124.4, while the 52-week low is ₹49.51. Currently trading at ₹55.79, the stock is 8.4% away from its 52-week low and 55.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Valiant Laboratories Ltd stock at ₹55.79 depends on multiple factors. The stock is currently trading with a P/E ratio of 2524.21 and P/B ratio of N/A. Today's performance shows a gain of 6.31%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Valiant Laboratories Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹55.79, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Valiant Laboratories Ltd's key financial metrics include: P/E Ratio: 2524.21, P/B Ratio: N/A, ROE: 0.00%, ROCE: -0.95%, Dividend Yield: 0.00%, EPS: ₹-0.05, Book Value: ₹50.08, Debt-to-Equity: 0.52, and Current Ratio: N/A. The company's market cap stands at ₹321.37 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Valiant Laboratories Ltd stock opened at ₹53.01 and is currently trading at ₹55.79, showing a gain of ₹3.31 (6.31%). The intraday high is ₹56.98 and low is ₹53.01. The trading volume stands at 11,805 shares, indicating moderate market participation today.
Valiant Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 2524.21, which means investors are willing to pay ₹2524.21 for every ₹1 of earnings. With an EPS of ₹-0.05, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Valiant Laboratories Ltd has a market capitalization of ₹321.37 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹55.79) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Valiant Laboratories Ltd has a book value of ₹50.08 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹55.79, which is 11.4% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Valiant Laboratories Ltd has a Return on Equity (ROE) of 0.00% and Return on Capital Employed (ROCE) of -0.95%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Valiant Laboratories Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Valiant Laboratories Ltd has a debt-to-equity ratio of 0.52, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Valiant Laboratories Ltd has an Earnings Per Share (EPS) of ₹-0.05, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹55.79 and P/E ratio of 2524.21, investors are paying 2524.21 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Valiant Laboratories Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Valiant Laboratories Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Valiant Laboratories Ltd stock, consider: 1) Fundamental Analysis - Review P/E (2524.21), ROE (0.00%), debt-to-equity (0.52), and growth rates. 2) Technical Analysis - Check 52-week range (₹49.51 - ₹124.40), moving averages, and chart patterns. 3) Valuation - Compare current price (₹55.79) with book value (₹50.08) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Valiant Laboratories Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹55.79 is 458x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Valiant Laboratories Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹49.51 - ₹124.40). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.52 indicates leverage. 4) Liquidity Risk - Based on trading volume of 11,805 shares. 5) Valuation Risk - P/E of 2524.21 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Valiant Laboratories Ltd operates in the industry with key metrics: P/E ratio of 2524.21, ROE of 0.00%, market cap of ₹321.37 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.52), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Valiant Laboratories Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹55.79, with a 52-week range of ₹49.51 to ₹124.40. Based on fundamentals like P/E (2524.21), ROE (0.00%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Valiant Laboratories Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹55.79. 2) Fundamental Deterioration - Declining ROE (currently 0.00%), increasing debt (D/E: 0.52), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Valiant Laboratories Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu